Cilmostim

Summary

Cilmostim (CHEMBL2108239) is a phase-3 clinical-stage protein; indicated across 1 condition including presbyopia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108239
Name	Cilmostim
Type	Protein
Max phase	3

Also known as: Cilmostim, Csf-1, M-csf, Rhm-csf, CILMOSTIM, M-CSF

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
presbyopia	3	MONDO:0001330	MONDO:0001330

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04599933	PHASE3	COMPLETED	An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)
NCT04599972	PHASE3	COMPLETED	An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
NCT05393895	PHASE3	COMPLETED	An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
NCT03885011	PHASE2	COMPLETED	A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).